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Abstract
Background: An algorithm instituted following Xpert MTB/RIF (Xpert) introduction in South Africa advocates for
treating all Xpert rifampicin resistant patients as MDR-TB cases while awaiting confirmation by phenotypic or
genotypic drug susceptibility testing. This study evaluates how the Xpert has influenced the diagnosis and
management of drug resistant TB in the highest burdened district of KwaZulu-Natal Province.
Methods: Data was retrospectively collected from all patients with rifampicin resistance on Xpert performed
between March 2011 and April 2012. Xpert results were compared with those of phenotypic and/genotypic drug
susceptibility testing. Patients’ records were used to determine the time to treatment initiation.
Results: Out of 637 patients tested by Xpert, 50% had confirmatory results, of which a third were sent on the same
day as Xpert test. The rate of rifampicin discordance and monoresistance was 8.8% and 13.4% respectively and
there was no difference between phenotypic and genotypic confirmation. Among those who had been initiated on
treatment, 28%, 40%, 21% and 8% of patients commenced within 2 weeks, 1 month, 2 months and 3 months of
Xpert testing respectively, while the remaining 3% were observed without treatment.
Conclusion: This study emphasizes the importance of complying with the algorithm in confirming all Xpert rif
resistant cases so as to ensure proper management of these patients. Despite the rapidity of the Xpert results, only
about 70% of patients had been initiated treatment at one month. Therefore there is a definite need to improve
the health systems in order to improve on these delays.
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Background
Whilst South Africa is the third country with the highest
burden of tuberculosis (TB) in the world, following India
and China, it is also overburdened with an HIV prevalence
of 17.9% equating to 17% of the global burden of HIV
[1-3]. More than 60% of TB infected patients in South
Africa are co-infected with HIV, further complicating the
diagnosis and management of these two diseases. The
country is ranked fifth in the world with highest drug re-
sistant TB cases and the multi-drug resistant (MDR) TB
prevalence is 1.8% among new TB cases and 6.7% among
TB retreatment cases [4]. The KwaZulu-Natal (KZN)
province alone which is also disproportionally afflicted
with HIV and TB co-infections, carries 36% and 37% of
the country’s burden of MDR and XDR-TB cases respect-
ively [5]. It was this overwhelming burden of disease that
prompted the South African Department of Health
to introduce the Xpert MTB/RIF (Cepheid GeneXpert,
Sunnyvale, Ca, USA) in 2011 to improve the diagnosis of
TB and detection of drug resistant TB.
The introduction of the Xpert MTB/RIF (Xpert) test
replaces the two sputum smears in the initial diagnoses
of TB. All cases detected as having rpoB mutations on
this assay are initiated on MDR TB treatment while a
second sample is sent for culture and drug susceptibility
testing (DST) to confirm these results [5]. This means
that patients can effectively be started on MDR-TB treat-
ment within a week instead of the long waiting periods
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associated with culture results, thus reducing patient loss to
follow up related to long turnaround time results [6]. The
mean delay in starting MDR-TB treatment has previously
been 12 weeks [7] prior to the introduction of decentralised
MDR-TB treatment sites which increased the capacity for
earlier treatment initiation. Decentralisation in KZN re-
sulted in an improved but still unacceptable time to treat-
ment of 72 versus 93 days in centralised site [8].
Despite the fact that rifampicin resistance has been
used as a surrogate marker for MDR-TB as more than
90% of these cases are associated with isoniazid (INH)
resistance [9-11], there is a growing concern for the
increasing rifampicin monoresistance in South Africa
[12,13]. This implies that if these patients were treated
as having MDR-TB, a significant number would be inad-
vertently denied INH. Although several studies have
shown a high Xpert rifampicin resistance specificity (94-
100%), the positive predictive value remains low in areas
with a low prevalence of MDR-TB like South Africa
[14,15], hence the need for confirmatory culture. Our
guidelines for drug resistant TB require that the con-
firmatory sample be sent to the laboratory when the pa-
tient returns for the Xpert results. There are no studies
that have assessed the frequency of return for second
sampling and the extent of delay thereof.
The aim of this study was to ascertain how the introduc-
tion of Xpert has influenced the health care practices in
the management of MDR-TB in KZN by determining the
rate of patient return for the confirmatory culture sample,
whether it could be linked to the initial GXP result and
the period it takes before starting MDR-TB treatment. In
addition to this, we also aim to determine the rate of




The study was an observational retrospective study using
data of all patients who showed rifampicin resistance on
the Xpert test performed on the GeneXpert at the Prince
Mshiyeni Memorial Hospital (PMMH) laboratory over
one year period between March 2011 and April 2012.
Study setting
PMMH is a public regional hospital located in the biggest
township in KZN in Durban. It has 1200 beds which serve
the surrounding community including 18 primary health
clinics. It was selected for the placement of the GeneXpert
48 infinity due to the high burden of TB and HIV in the
area. Surrounding hospitals in the sub-district also send
their sputum specimens for processing at this Hospital.
Patients diagnosed with drug resistant TB are further re-
ferred to a 320 beds hospital that manages drug resistant
TB patients.
Laboratory procedures
The National Health Laboratory Service (NHLS) operates
on a national laboratory information system (LIS) which
allows tracking of patients results as all the public labora-
tories utilise this LIS. The Xpert MTB/RIF test was per-
formed according to the manufacturer’s instructions. The
GeneXpert infinity is interfaced with the LIS; therefore all
tests performed by the instrument are available on the sys-
tem. All the data from the LIS is processed centrally by
the central data warehouse (CDW). The Xpert results are
printed directly at the patient facilities using SMS printers,
while printed copies are distributed from the laboratory to
the healthcare facilities on the next day.
The Mycobacterium tuberculosis (MTB) culture and
drug susceptibility testing (DST) was performed at the
Central Academic Laboratory using the standard labora-
tory procedures for culture and indirect line probe assay
(LPA) [GenoType MTBDRplus assay, Hain Lifescience,
Nehren, Germany] and/the 1% indirect agar proportion
method (APM) using Middlebrook 7H10 agar. This la-
boratory is a quality assured reference laboratory for the
KZN province. Culture for TB was performed using BAC-
TEC mycobacteria growth indication tubes (MGIT) 960
system [BACTEC MGIT Becton Dickinson, USA]. Posi-
tive cultures were tested for susceptibility to first line TB
drugs using the LPA first in order to confirm resistance
to rifampicin and isoniazid. Where these results demon-
strated resistance to any of the drugs tested, further test-
ing for both first and second line drugs was performed
using APM. Samples coming from patients in the MDR-
TB units were tested using APM with no preceding LPA.
Data collection and analysis
The Xpert rifampicin resistant data was obtained from the
CDW and from the LIS. Demographic data was used to
link Xpert results with the culture results. Patients that
could not be reliably linked were regarded as untraceable
and excluded from further analysis. All samples registered
in the laboratory within 48 hours of each other were
regarded as same day samples. Where both the LPA and
APM were performed, the result of the APM was used for
comparison with the Xpert result, where only LPA
was done; it was used for comparison. The information
containing the date of commencing MDR TB treatment
was collected from the TB register at admitting Hospital.
Patients were traced up to 3 months from the date of
Xpert sample and cases which were not identified on the
TB register after 3 months were considered as missing.
For those patients with both the Xpert and culture re-
sults, the period between the two samples was determined.
Descriptive statistics were used to report proportions of pa-
tients who measured rifampicin monoresistant, MDR-TB
and rifampicin susceptible on both LPA and DST tests. A
Chi square test for agreement was used to compare the
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agreement of results between the LPA and APM diagnostic
methods. The amount of time taken to commence treat-
ment was calculated by subtracting the date of Xpert re-
gistration in the laboratory from the date of starting TB
treatment. Time to treatment was categorized and de-
scribed Analysis was performed using SAS version 9.3 (SAS
Institute Inc., Cary) and graphs were drawn using Microsoft
Excel.
The study protocol was approved by the University of
KwaZulu-Natal Biomedical Research Ethics Committee.
Results
Out of 34 444 patients tested for TB using Xpert at
PMMH laboratory between March 2011 and April 2012,
5870 were positive for TB. Of these, 637 showed rifampi-
cin resistance but after excluding the untraceable results,
only 268 (42%) had a culture sample for comparison with
the Xpert and therefore eligible for further analysis
(Figure 1). About a third (32.8%) of the confirmatory
samples were submitted simultaneously with the Xpert
samples (paired samples) with an additional 20% being
sent within two weeks of Xpert (Table 1). Most of the
confirmatory samples submitted within 2 weeks of Xpert
(63%) were from the same hospital where Xpert sample
was collected while those collected at a different hospital
to that of Xpert accounted for the majority of those col-
lected later (Figure 2).
Most of the rifampicin resistance confirmation was per-
formed using APM. Table 2 shows the summary of the
LPA and APM results for the Xpert rifampicin resistant
samples. The Xpert MTB/RIF assay showed 8.8% discord-
ance when compared to culture and LPA/APM and the
overall rate of rifampicin monoresistance was 13.4%.
When comparing the LPA and APM results for the
144 samples where both were available, 87% (126) of
LPA results agreed with APM (Table 3). An agreement
test failed to show a significant difference in agreement
between LPA and APM, however there does appear to
be a trend (p = 0.062).
Out of the 268 patients with confirmatory samples, 98
(36%) were not found on the MDR-TB treatment regis-
ter within 3 months of Xpert samples. Of the remaining
170 patients that started treatment, 28% were started
within two weeks of Xpert test, with the majority (68%)


























Figure 1 Flow diagram of results of patients with Rifampicin resistance on Xpert.
Dlamini-Mvelase et al. BMC Infectious Diseases 2014, 14:442 Page 3 of 7
http://www.biomedcentral.com/1471-2334/14/442
already started treatment within a month of Xpert
(Table 4).
Discussion
This study reveals lessons that have been learnt during
the initial introduction of Xpert. Considerable gaps were
identified regarding compliance with the current na-
tional guidelines in the diagnosis and management of
MDR-TB using Xpert [16].
There was poor adherence to the Xpert algorithm espe-
cially with sending a confirmatory sample. Even though
we could not show the reasons behind this finding, several
explanations could be attributed to this non-compliance,
including poor training of health care workers at the time
of Xpert introduction. The rollout of Xpert preceded the
training of clinicians; this may have lead to poor under-
standing of the role of the assay in the diagnosis of DR
TB. Other reasons could be patient related, as shown in
several studies conducted in South Africa where the initial
defaulter rate was between 16 and 17% [17,18]. The ma-
jority of the patients in these studies could not be inter-
viewed in order to find reasons behind their default
because they were either lost to follow up (45%), or
demised prior to starting treatment (24%). In recognition
of this, the provincial department of health in collabor-
ation with the laboratory services has recently established
an alert system where health care workers at patient facil-
ities are alerted of MDR TB results. This should lead to
prompt tracing of patients for further management.
A significant number of samples were submitted sim-
ultaneously for both Xpert and culture. While this may
have ensured timely confirmation of Xpert rifampicin
resistant cases, both tests were performed concurrently
without considering the Xpert results. This practice
could lead to wastage of resources where Xpert results
do not require a confirmatory test. The Western Cape
which is one of the provinces in South Africa has a
protocol where two samples are submitted concurrently,
one for Xpert and should the rifampicin be resistant, the
other one is used for confirmation using LPA or APM
[19]. Should this practice be adopted by the rest of the
country, it could improve the confirmation of Xpert re-
sistant cases.
Our study shows a slightly lower concordance between
Xpert and culture than previously reported despite the
previous assay improvements made in 2010 [20]. Several
studies conducted in South Africa have shown excellent
Xpert rifampicin resistance specificity of between 99.4
and 99.5% [19,21]. However these studies used molecu-
lar assays (LPA and sequencing) which have recently
been proven to show a better concordance to Xpert than
the phenotypic assays [22]. Interestingly, as shown in
Table 3, out of the seven patients who had discordant
Xpert rifampicin resistance where both the LPA and
APM were performed for confirmation, only two were
sensitive to rifampicin on LPA while all were sensitive
on APM. We were unable to show any significant differ-
ence between using the phenotypic or genotypic test for
confirmation because of the small number of cases.
Table 1 Time between date of Xpert and culture samples
Period between samples Number of patients Percentage
Culture prior to GXP 22 8.2%
Paired samples 88 32.8%
0-2 weeks 53 19.8%
>2-4 weeks 55 20.5%
>4-8 weeks 26 9.7%
>8-12 weeks 9 3.4%
>12 weeks 15 5.6%
Total 268 100
Period between Xpert and culture samples
Figure 2 Site and timing of collection of Xpert and Confirmatory samples.
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Traditional phenotypic DST is considered the gold
standard for TB drug resistance testing; however studies
are now showing cases of TB isolates that have rpoB
mutation that are not detected by phenotypic assays
[23-26]. Williamson et al. [26] reported cases with INH
mono-resistance that demonstrated genotypic rifampicin
resistance while phenotypically susceptible to rifampicin
on proportion method using MGIT. These patients sub-
sequently failed treatment. Almost half of our culture
confirmed rifampicin susceptible (discordant) cases were
resistant to INH. The isolates were not available for se-
quencing, but, further studies that look at the presence
of these low level mutations are warranted.
The discordance of rifampicin resistance can lead to
diagnostic and management dilemmas because DR-TB
management has serious consequences. Patients are not
only given more toxic and less effective second line drugs,
but they are also subjected to socioeconomic disruption as
they have to get their treatment from the designated
MDR-TB treatment facilities. Given the limitations of the
available laboratory diagnostic assays, discordance be-
tween Xpert and phenotypic testing require confirmation
by another molecular assay. Additionally, larger studies
are essential to ascertain the clinical significance of such
cases.
Our findings demonstrate a high rate of rifampicin
monoresistance (13.4%) and there was no statistical dif-
ference between using LPA and APM, hence both these
test were reliable in confirming MDR TB. A study con-
ducted by Coovadia and colleagues in our setting be-
tween 2007 and 2009, showed the overall rifampicin
monoresistance rate of 8.8% [13]. This increasing rifam-
picin resistance show that rifampicin can no longer pre-
dict MDR TB in a significant number of patients, further
emphasizing the importance of performing confirmatory
DST. Whereas these patients might benefit from adding
isoniazid on their MDR TB treatment regimen while
awaiting culture and DST results, the majority of pa-
tients would be exposed to this drug unnecessarily, par-
ticularly because most of these patients are already on
multiple drugs due to co-infection with HIV.
Among patients found on the TB register, 68% started
treatment within one month of Xpert test. Although this
is a major improvement when comparing to the pre-
Xpert period [7,27], the delay is still substantial consid-
ering the rapidity of the Xpert together with the
decentralization of the MDR TB treatment. In a feasibil-
ity study conducted by Boehme et al. [28], Xpert re-
duced time to treatment in smear negative TB from
56 days to 5 days, the latter has also been advocated by
the SA department of Health as the cut off period for
starting MDR TB treatment. The TB/HIV care project in
rural KZN was able to put 89% of patients on treatment
within five days [29]. This was achieved by using Xpert
for diagnosis, while the results were communicated
using cell phones to link patients with community health
workers, clinics and laboratory. This could be adopted
by the department of health in order to improve time to
treatment initiation. An efficient health care system is
crucial to achieve a significant impact on drug resistant
TB management.
A number of studies performed in South Africa have
shown that when Xpert is done closest to the point of
care, treatment can be initiated on the same day [30-32].
An average of 71% of results achieved the targeted turn-
around time of 48 hours at PMMH laboratory over the
past year. Lawn and colleagues showed that performing
Xpert at a centralised laboratory increases the turnaround
time of results by up to four days, which could impact on
the initiation of treatment [14,33]. Whilst these studies
mainly involved patients with drug sensitive TB, further
decentralisation of MDR TB treatment sites together with
Table 2 Summary of Culture and LPA/APM in patients with rifampicin resistant Xpert
Test Rifampicin sensitive Rifampicin monoresistant MDR-TB Inconclusive
Culture and LPA (N = 180) 14 (7.8%) 30 (16.7%) 130 (72.2%) 6 (3.3%)
Culture and APM (N = 226) 11 (4.9%) 31 (13.7%) 184 (81.4%) 0 (0.0%)
Total Confirmed (N = 262) 23 (8.8%; 35 (13.4%; 204 (77.8%; N/A
5.4-12.2%) 9.2-17.5%) 72.8-82.9%) N/A
Table 3 Comparison of LPA and APM results
Number of samples APM results
LPA results RIF susceptible RIF monoresistant MDR-TB Inconclusive
RIF susceptible 2 0 0 0
RIF monoresistant 3 17 6 0
MDR-TB 1 2 107 0
Inconclusive 2 3 1 0
Boldface shows agreement between LPA and APM results.
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transfer of Xpert to the near point of care could bring sig-
nificant improvement to these treatment initiation delays.
The number of patients that were untraceable is a cause
for concern. These were patients who did not have
enough details on the computer system to link the Xpert
result to the culture result. This reflects poor data captur-
ing and matching these result would erroneously cause in-
crease in the rate of discordant result. Given that patients
with MDR TB are treated in designated facilities which
are different to the patient’s local facility, it becomes very
important to have correct and complete patient details so
as to follow up on the results. Failing to do so may results
in repeated testing which not only leads to wastage but
may also cause delays in changing to appropriate treat-
ment where necessary.
There were several limitations to this study. Even
though the matching of Xpert and culture results was
carefully carried out and results with insufficient details
were excluded from analysis, this method is not perfect;
hence there may still be minor mismatching. We studied
the period of the initial roll out of the Xpert; there may
have been subsequent improvements in the management
of MDR TB patients as the test was getting more recog-
nised throughout the country. Finally, while the area
studied is a high burden TB region, our findings may
not be representative of the whole province.
Conclusion
A few lessons have been learnt following the introduction
of Xpert. Introducing a new test requires proper prepar-
ation and training of those involved in order to ensure
compliance with the stipulated guidelines. Our findings
show a significant amount of discordance between Xpert
and phenotypic and/ genotypic drug susceptibility testing
which underscores the importance of taking a second
sample in cases of Xpert rifampicin resistance. This will
also assist in detection of the increasing rifampicin mo-
noresistance. Studies ascertaining the causes and clinical
significance of discordance between phenotypic and geno-
typic assays are warranted in order to solve the diagnostic
dilemmas that often accompany such results. Despite hav-
ing a rapid diagnostic tool which can generate results in a
few hours, system associated challenges continue to result
in delays in treatment initiation.
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